Application of adipokine C1q / TNF-related protein 9 (CTRP-9) in enhancing T cell immunotherapy effect
CN121265757BActive Publication Date: 2026-10-16EAST CHINA NORMAL UNIV
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202511650678.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-11-12
- Publication Date
- 2026-10-16
- Estimated Expiration
- 2045-11-12
AI Technical Summary
Technical Problem
然而，关于CTRP-9在免疫系统尤其是T细胞功能调控方面的作用目前尚缺乏系统性研究，迄今未见其在增强细胞免疫治疗效果中的应用报道
Benefits of technology
[0037] Compared with existing technologies, the beneficial effects of this invention include: proposing a novel function of CTRP-9 in immunotherapy, providing new targets and methods of action, and proposing that CTRP-9 can enhance T cell function in a multi-level and all-round way; it also proposes that CTRP-9 can be used as a universal enhancer to significantly improve the anti-tumor function of CAR-T cells.
✦ Generated by Eureka AI based on patent content.
Abstract
The application discloses application of an adipokine C1q / TNF related protein 9 (CTRP-9) in enhancing T cell immunotherapy, relates to a new application of the adipokine C1q / TNF related protein 9 (CTRP-9) in regulating T cell function, and the CTRP-9 is an immune regulation molecule secreted by adipose tissue. The application proposes that exogenous supplement of the CTRP-9 can effectively enhance the effect intensity of T cells in an anti-tumor immune response, and promote T cell activation and proliferation. Meanwhile, the CTRP-9 can also be used as a CAR-T cell enhancer, so that the immunotherapy effect is improved. The method can be applied to a T cell based immunotherapy system, and provides a new regulation path and target for improving the T cell immunotherapy effect.
Need to check novelty before this filing date? Find Prior Art